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Preeclampsia is one of the leading causes of maternal morbidity/mortality. The pathogenesis of preeclampsia is still under
investigation. The aim of this paper is to present the molecular mechanisms implicating in the pathway leading to preeclampsia.
1.Introduction
Preeclampsia is one of the leading causes of maternal mor-
bidity/mortality and preterm delivery worldwide [1]. It
is a syndrome deﬁned by the onset of hypertension
(≥140/≥90mmHg) and proteinuria (≥0,3gr/24h) after 20
weeks of gestation in a previously normotensive woman that
also may be associated with myriad, other signs and symp-
toms, and often with subnormal fetal growth [2, 3]. Most
commonly, preeclampsia occurs in healthy nulliparous wo-
men. However, multiparous pregnant women with a new
partner have an increased risk of preeclampsia similar to that
of nulliparous women [4]. Women with a history of preecla-
mpsiainapriorpregnancyareatincreasedriskofdeveloping
preeclampsia in future pregnancies [5]. A history of pre-
eclampsia in the father’s mother also confers an increased
risk [6]. Several medical conditions, such as chronic hyper-
tension,diabetesmellitus,renaldisease,andhypercoagulable
states are associated with increased preeclampsia risk [7, 8].
Additionally, obstetrical conditions with increased placental
mass increase the risk of preeclampsia. These include
hydatidiform mole [9] and multifetal gestation [10].
Delivery of the placenta remains the only known treat-
ment for this clinical disease, suggesting that the placenta is
the principal contributor to the pathogenesis of preeclamp-
sia. It is well known that the ﬁrst step for the development of
preeclampsia is the inadequate placental cytotrophoblast in-
vasion, impaired trophoblast invasion, and inadequate ma-
ternal spiral artery remodeling which results in placental is-
chemia and hypoxia. However, placental ischemia does not
alwaysgeneratetheclinicalsymptomsofpreeclampsia.Many
molecular mechanisms are contributed to the pathogenesis
of preeclampsia. Altered angiogenic balance, systemic in-
ﬂammation, dystregulation of renin-angiotensin system, and
placental hypoxia and ischemia are mechanisms which con-
tribute to the pathogenesis of pre-eclampsia, although it is
unknown whether the mechanisms act independently or
have synergistic eﬀects.
2.AlteredAngiogenicBalance
2.1. Angiogenic Factors. A variety of angiogenic factors are
produced from the human placenta. The most important be-
tween them are the vascular endothelial growth factor
(VEGF) and the placental growth factor (PIGF) [11]. VEGF
isanendothelial-speciﬁcmitogenthatplaysakeyroleinpro-
moting angiogenesis. VEGF stabilizes endothelium in mat-
ure blood vessels [12]. VEGF’S activities are mediated pri-
marily by its interaction with two high-aﬃnity receptors ty-
rosine kinases—kinase-insert domain region (KDR or VEGF
R-2) and fms-like tyrosine kinase-1 or ﬂt-1. Both receptors
are expressed on vascular endothelial cell surface [13]. PIGF
is also an angiogenic growth factor that is thought to amplify
VEGF signalling by displacing VEGF from the ﬂt-1 receptor
and allowing it to bind to the more active kinase-insert do-
main (KDT) receptor [14, 15].
Recent research has shown that soluble ﬂt-1 is released
by the placenta into the maternal circulation and, that is,
contributes to the hypertension, proteinuria, and endothelial
cell dysfunction associated with preeclampsia [16]. sﬂt-1
antagonizes both VEGF and PIGF by binding them in2 Journal of Pregnancy
thecirculationandpreventinginteractionwiththeirendoge-
nous receptors [17, 18]. New variants of sﬂt-1 have been
discovered such as sﬂt1–14, which is also a potent VEGF
inhibitor [19, 20]. The level of SFLt-1 in the plasma of
women with preeclampsia is elevated and that of VEGF is
diminished in comparison with that of women with com-
plicated pregnancies [21]. Furthermore, administration of
sﬂt-1 to rats resulted in elevated blood pressure and pro-
teinuria,indicatingthatexcessiveplacenta-derivedsﬂt-1max
contributes to preeclampsia [21].
Factors responsible for excessive production of self-1 in
preeclampsia have not been identiﬁed. However, recently it
hasbeenfoundthatangiotensinIItype1(AT)receptorauto-
antibodies which occur in women with preeclampsia con-
tribute to increased production of sﬂt-1. Thus, IgG from
womenwithpreeclampsiastimulatesthesynthesisandsecre-
tion of sﬂt-1, via AT1 receptor activation in human placental
villous explants and human trophoblast cells. Another
factor which contributes to increased production of sﬂt-1 is
the hypoxic placenta [22]. Under other pathophysiological
conditions such as cancer and hypoxia which generally stim-
ulates angiogenic signalling, it remains poorly understood
why hypoxic placenta produces the molecules that suppress
angiogenesis in preeclampsia [23].
Soluble endoglin is another antiangiogenic protein,
which acts to get it with sﬂt-1 to induce a severe preeclamp-
sia-like syndrome in pregnant rats. Circulating soluble endo-
glin levels increased markedly beginning from 2 to 3 months
before the onset of preeclampsia. An increased level of solu-
ble endoglin was usually accompanied by an increased ratio
of sﬂt-1 [24].
Experiments data have shown that VEGF stimulates the
production of both nitric oxide (NO) and PGI2 [25]. On the
other hand, a high concentration of asymmetric dimethy-
larginine (ADMA), an endogenous inhibitor of endothelial
nitricoxidesynthase,hasbeenfoundinpreeclampticwomen
[26].
Women with bilateral notches who later developed pree-
clampsia had a striking elevation in the concentration of the
NO synthase inhibitor [27].
ADMA is normally metabolized to citrulise through
the action of dimethylarginine-dimethylaminohydrolase I, II
(DDAH I, II). Oxidative stress seen in preeclampsia dimin-
ishes the action of the alone enzymes leading to high concen-
tration of ADMA [27].
3.TheRole of RelaxininPreeclampsia
Relaxin is produced by the corpus luteus of the ovary and
rises early in pregnancy, and chorionic gonadotropin pro-
duced by the placenta is a major stimulus for relaxin secre-
tion during pregnancy.
Relaxinhasrenalvasodilatoryeﬀect[28],anditalsodim-
inishes the relaxin vasoconstrictor response to angioten-
sin II. Moreover, reduced myogenic reactivity of small renal
arteries is observed after relaxin administration [29, 30].
Recently, it has been proposed that relaxin via relaxin recep-
torupregulatesvasculargelatinaseactivityduringpregnancy,
contributing to renal vasodilation through activation of en-
dothelial endothelin B (ETB) receptor which activates nitric
oxide synthase III and the production of NO [31]. Thus,
increased vascular gelatinase activity by relaxin is thought to
be a proximal step in the vasodilatory pathway of pregnancy
[32].
Circulating levels of immunoreactive relaxin have been
reported to be similar in women with preeclampsia and nor-
mal pregnancy [33]. However, whether circulating relaxin
bioactivity may be deﬁcient during the disease is uncertain
[34]. Furthermore, mutations or polymorphisms of the ETB
receptor or of endothelial NO synthase that reduce activity
may predispose a woman to preeclampsia by impairing tro-
phoblast invasion on the one hand or by compromising ma-
ternal endothelial behaviour on the other [35, 36].
4. Inﬂammatory Cytokinesin
the Pathophysiology of Preeclampsia
Reduceduterineperfusionduringpregnancyisanimportant
initialling event in preeclampsia. Inﬂammatory cytokines are
thought to link placental ischemia with cardiovascular and
renal dysfunction [37]. In normal pregnancy TNF-α is low in
the ﬁrst trimester and subsequently increases with advancing
gestation age [38]. Some studies report higher TNF-α levels
in women with established preeclampsia [39, 40]. Increased
levels of TNF-α antigen and mRNA have been described in
placental tissue from preeclamptic women [41].
Because TNF-α may impair insulin signalling, inhibit
lipoprotein lipase, induce PAI-1, and directly contribute to
endothelial dysfunction, this cytokine may be involved in the
pathogenesis of preeclampsia [42].
There are also ﬁndings showing that chronic infusion
of IL-6 into normal pregnant rats stimulates the renin-
angiotensin system (RAS) [37].
Natural killer (NK) cells, dendritic cells, and macroph-
ages are mediators of innate immunity. Macrophages and
dendritic cells are the major antigen-presenting cells in the
uterus,andtheyfacilitateadaptationoftheimmuneresponse
to prevent rejection of the embryo [43].
Several studies have found a statistically signiﬁcant in-
crease in macrophages and dendritic cells in preeclamptic
placentas compared to placentas from normotensive preg-
nancies [43, 44]. An increase in the concentration of cytoki-
nes, molecules capable of recruiting macrophages, and den-
triticcellshasalsobeenfoundinpreeclampticplacentas[44].
The increased presence of cytokines, macrophages, and
dendritic cells in preeclamptic placentas supports the hypo-
thesis that an inﬂammatory milieu presents in women with
preeclampsia [44].
5.ActivationofRenin-Angiotensin
System (RAS)
Renin-angiotensin system is one that controls blood pressure
[45].TheexpressionofrenninmRNAwasdetectedinhuman
deciduas,macrophages,chorioamnioticmembrane,andvas-
cular smooth muscle cells [46].Journal of Pregnancy 3
A n g i o t e n s i nI Ir e c e p t o rt y p eI( A T 1) was shown to be lo-
calized both in villous and extravillus trophoblasts, and this
AT1 responds to exogenously administrated angiotensin II
[47].
The circulating level of angiotensin II increases as the
pregnancy advances [48]. In preeclampsia, the circulating
level of angiotensin is rather decreased [49], despite the fact
that the vascular sensitivity to angiotensin is elevated in
hypertensive pregnant women.
The AT1 receptor gene expression was higher in placenta
than in deciduas for both normal and preeclamptic wo-
men. However, the deciduas of preeclamptic women has a
signiﬁcantly higher AT1 receptor gene expression than nor-
mal pregnant women [50]. It has been found that the gene
encoding the AT1 receptor was upregulated in the deciduas
of preeclamptic women but not in normal control [51]. Cir-
culating agonistic autoantibodies directed at the angiotensin
II type 1 receptor (AT1-AAs) have been discovered in women
with preeclampsia [52].
Thus the increased decidual AT1 expression in pre-
eclampsia may be the initial step for a profound RAS activa-
tion.Furthermore,thepresenceofAT1-AAs isabletoactivate
cells via the AT1 receptor and initiate signaling events that
could contribute to development of preeclampsia. Thus,
releaseofsolubleﬂt-1canbetriggeredbyangiotensinIIstim-
ulation, raising an imbalance between angiogenic vascular
endothelialgrowthfactorsandantiangiogenicsolublefactors
[21]. Zhou et al. [21] have shown that the inhibition of
AT1 administration of losartan or FK506 resulted in reduced
SVEGFR-1. Thus, maternal SVEGFR-1 can be elevated not
onlybypoorplacentationbutalsobyAT1 activationinwhich
angiotensin II and AT1-AAs are potentially implicated.
6. Placental HypoxiaandIschemia
Impaired trophoblast invasion and inadequate maternal spi-
ral artery remodelling result in placental ischemia and hyp-
oxia. It is unknown, however, whether abnormal placenta-
tion leads to systemic vascular dysfunction and the appear-
ance of preeclampsia.
Defective trophoblast invasion and inadequate maternal
spiral remodelling frequently result in intrauterine growth
restriction or other complications of pregnancy (preterm
labor e.g.) without preeclampsia even to normal full-term
pregnancy [53]. Women living in high altitudes have an in-
creased risk of developing preeclampsia [54], while cigarette
smoking is associated with a reduced risk for preeclampsia
[55]. Experiments in animals suggest that placental hypoxia
contributes to preeclampsia by upregulating soluble antian-
giogenic factors, inﬂammatory cytokines, downregulating
angiogenic, and vasodilator factors [56].
Furthermore, in pregnant mice, an absence of 2-methox-
yestradiol(2-ME),anaturalmetaboliteofestradiol,resultsin
a deﬁcient of catechol-o-methyltransferase (COMT). These
animals showed a preeclampsia-like phenotype [57]. The
addition of 2-ME was shown to improve preeclampsia and
suppress placental hypoxia and sﬂt-1 expression [57]. It is,
however, unclear whether or not decreased COMT is the
cause of the consequence of impaired placentation.
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